Posted by Michael Wonder on 01 Dec 2021
EMA validates Atara Biotherapeutics' marketing authorisation application for tabelecleucel for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease
30 November 2021 - First ever off the shelf allogeneic T-cell therapy to be reviewed by any regulatory agency in the World.
Atara Biotherapeutics today announced that the marketing authorisation application for tabelecleucel (tab-cel) has been fully validated by the EMA.
